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Background: Since proteins involved in chemotherapy drug pharmacokinetics and pharmacodynamics have a
strong impact on the uptake, metabolism, and efflux of such drugs, they likely play critical roles in resistance to
chemotherapy drugs in cancer patients.
Methods: To investigate this hypothesis, we conducted a whole genome microarray study to identify difference in
the expression of genes between isogenic doxorubicin-sensitive and doxorubicin-resistant MCF-7 breast tumour
cells. We then assessed the degree of over-representation of doxorubicin pharmacokinetic and pharmacodynamic
genes in the dataset of doxorubicin resistance genes.
Results: Of 27,958 Entrez genes on the array, 7.4 per cent or 2,063 genes were differentially expressed by≥ 2-fold
between wildtype and doxorubicin-resistant cells. The false discovery rate was set at 0.01 and the minimum p value
for significance for any gene within the “hit list” was 0.01. Seventeen and 43 per cent of doxorubicin
pharmacokinetic genes were over-represented in the hit list, depending upon whether the gene name was
identical or within the same gene family, respectively. The most over-represented genes were within the 1C and 1B
families of aldo-keto reductases (AKRs), which convert doxorubicin to doxorubicinol. Other genes convert
doxorubicin to other metabolites or affect the influx, efflux, or cytotoxicity of the drug. In further support of the role
of AKRs in doxorubicin resistance, we observed that, in comparison to doxorubicin, doxorubincol exhibited
dramatically reduced cytotoxicity, reduced DNA-binding activity, and strong localization to extra nuclear lysosomes.
Pharmacologic inhibition of the above AKRs in doxorubicin-resistant cells increased cellular doxorubicin levels,
restored doxorubicin cytotoxicity and re-established doxorubicin localization to the nucleus. The properties of
doxorubicinol were unaffected.
Conclusions: These findings demonstrate the utility of using curated pharmacokinetic and pharmacodynamic
knowledge bases to identify highly relevant genes associated with doxorubicin resistance. The induction of one or
more of these genes was found to be correlated with changes in the drug’s properties, while inhibiting one specific
class of these genes (the AKRs) increased cellular doxorubicin content and restored drug DNA binding, cytotoxicity,
and subcellular localization.
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Doxorubicin is a DNA-binding, topoisomerase II inhibi-
tor [1,2], which is among the most effective chemother-
apy drugs in cancer treatment [1,3]. However, intrinsic
or acquired resistance to doxorubicin in patient tumours
is common, resulting in treatment failure and disease
progression. Multiple mechanisms for doxorubicin re-
sistance have been identified in vitro, such as the
increased expression of drug transporters [4-7], altera-
tions in doxorubicin metabolism [8] or localization
[9,10], and defects in the drug’s ability to induce apop-
tosis [11]. Unfortunately, progress in restoring drug sen-
sitivity for drug-resistant tumours, particularly by
inhibiting drug efflux transporters, has been incremental
at best [12,13]. This limited progress demands that a
more nuanced approach be taken, including the identifi-
cation of all proteins that likely affect the pharmacokin-
etics and pharmacodynamics of doxorubicin.
Genome profiling is a method that can provide data
on gene expression and/or allelic variations across bio-
logical samples, often using whole genome approaches.
This promises to be a great aid to oncologists in identi-
fying and treating drug-resistant tumours. Unfortunately,
this task is a difficult one, given the variability associated
with patient data sets and the large number of “false
positives” inherent in such approaches from by-stander
effects. One method to improve the identification of
genes relevant to a specific phenomenon such as doxo-
rubicin resistance is to pair knowledge of metabolic or
signal transduction pathways to gene expression data
[14]. In this study, we use full genome microarray ana-
lysis to compare gene expression between MCF-7 cells
selected for maximal resistance to doxorubicin (MCF-
7DOX2-12 cells) and equivalent cells selected for the same
number of passages in the absence of drug (MCF-7CC12
cells). After identifying genes having altered expression
in doxorubicin-resistant cells, we then used a well-known,
curated pharmacogenomics knowledgebase (PharmGKB)
to identify which of these genes play a role in doxorubicin
pharmacokinetics or pharmacodynamics, as these were
more likely to have a direct effect on doxorubicin efficacy.
This combination of full genome microarray analysis
identifying genes differentially expressed upon acquisition
of doxorubicin resistance with an assessment of over-
representation of doxorubicin pharmacokinetic or phar-
macokinetic genes in the dataset provided significant
insight into new pathways associated with doxorubicin
resistance. Moreover, extensive comparisons between
the biochemical properties of doxorubicin and one of
its metabolites (doxorubicinol) provided us with signifi-
cant insight into how a simple hydroxylation reaction
can strongly affect the biochemical and cellular proper-
ties of doxorubicin, including dramatically reduced
cytotoxicity, diminished DNA- binding activity, alteredcellular accumulation of the drug and altered subcellu-
lar localization.Results
Differentially expressed genes upon acquisition of
doxorubicin resistance
Using full genome Agilent microarrays and Partek
Genomics Suite, 2063 genes from a total of 27958
Entrez genes on the array (7.4%) were found to be dif-
ferentially expressed by ≥2-fold between MCF-7CC12 cells
MCF-7DOX2-12 cells. The false discovery rate was set at
0.01 and the minimum p value for significance for any
gene within the “hit list” was 0.01. The microarray data
was deposited in the NCBI Gene Expression Omnibus
(GEO) database, accession number GSE27254) in ac-
cordance with MIAME standards [15]. Access to the
microarray data can be obtained via the following url:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
dbezngycywquuhm&acc=GSE27254.
The identification of thousands of genes changing ex-
pression upon selection of MCF-7 cells for doxorubicin
resistance was similar to the numbers of genes observed
when these cells were selected for resistance to other
chemotherapy agents (data not shown). These findings
indicate that a significant amount of the transcriptome
appears altered as these cells are selected for doxorubi-
cin resistance. In addition to providing candidate genes
that may be involved in doxorubicin resistance, the
microarray data served to demonstrate that MCF-7DOX2
cells at selection dose 12 and MF-7CC cells (selected to
the same passage number in the absence of doxorubi-
cin) are isogenic, since the vast majority of genes
(92.6%) differed in expression by < 2-fold between the
two cell lines [see statistical analysis of microarray
(SAM) plots in Figure 1]. This suggests that observed
differences in gene expression are likely related to the
acquisition of doxorubicin resistance and not simply a
selection for a rare, unrelated cell type within the cell
population.
In examining the identities of genes exhibiting the
greatest changes in expression upon acquisition of doxo-
rubicin resistance, a number of these genes play a role in
doxorubicin metabolism. Consequently, we assessed the
extent of “over-representation” of doxorubicin metabol-
ism genes by comparing the names of differentially
expressed genes in the microarray “hit list” with those
listed in a curated list of genes associated with doxorubi-
cin pharmacokinetics or pharmacodynamics in tumour
cells and cardiomyocytes available on the Pharmacogen-
etics Knowledge Base (PharmGKB) [16]. This list can
be found at the url: http://www.pharmgkb.org/drug/
PA449412#tabview=tab5&subtab=33 and is depicted in
Additional file 1: Table S1. Figure 2 shows two pathway
Figure 1 Significance Analysis of Microarrays (SAM) graph for MCF-7DOX2-12 and MCF-7CC112 cells. Red or green points denote genes with
significant over- or under-expression in MCF-7DOX2-12 cells compared to MCF-7CC12 cells, while black points represent genes that do not show
altered expression.
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document the different proteins that impact on the up-
take, metabolism, and efflux of doxorubicin in cardio-
myocytes (A) and tumour cells (B). A comparison of a
list of these proteins (Additional file 1: Table 1) with
the list of genes significantly changed by ≥ 2-fold in
doxorubicin-resistant cells in the above microarray experi-
ment (p≤ 0.01) revealed that doxorubicin pharmacokinetic
and pharmacodynamic genes are highly over-represented
in the list of differentially expressed genes. Identical genes
or genes having the same family name on both lists are
depicted in bold, with the fold increase (+) or decrease (−)
in expression in the microarray experiment listed be-
side each gene. Additional file 2: Table S2 depicts the
results of our over-representation analysis. At a false
discovery rate of 0.01, 8 of the 46 genes listed in the
doxorubicin pharmacokinetics/ pharmacodynamics path-
ways (17%) were direct matches and 20 or 43% were
partial matches (same gene family). The p value for sig-
nificance of this over-representation relative to ran-
domly selected genes was 0.05 for identical matches
and < 0.0001 for either identical or partial matches. Since
these genes directly affect the uptake, efflux, metabolism
or cytotoxicity of doxorubicin, they have a strong poten-
tial to play a role in doxorubicin resistance. The identities
of these genes provide a compelling view of the various
mechanisms that likely play a role in the acquisition ofdoxorubicin resistance in breast tumour cells in vitro
(see discussion).
Several AKRs are over-expressed in MCF-7DOX2-12 cells
As previously demonstrated using a much smaller
microarray platform (1720 genes) [17], the “1C” family
of AKRs was observed to be over-expressed upon ac-
quisition of doxorubicin resistance. Moreover, as shown
in Additional file 1: Table S1, a variety of AKR family
members were among the most differentially expressed
genes upon acquisition of doxorubicin resistance in
MCF-7 cells. In these microarray studies, AKR1B1,
AKR1B10, AKR1C1, and AKR1C3 all had strongly ele-
vated expression (10.0-, 13.4-, 4.45-, and 4.71-fold, re-
spectively). As stated previously, the product of the
AKR family of genes facilitates the conversion of doxo-
rubicin to doxorubicinol [18]. Such a strong overex-
pression of multiple AKR transcripts in MCF-7DOX2-12
cells suggests that the AKRs may play a major role in
doxorubicin resistance.
Given that AKR “1C” isoforms are highly conserved
amongst each other [19] and given that, by BLAST ana-
lysis, the probes on the Agilent 4X44K arrays could not
distinguish between the four 1C transcripts, we designed
isoform-specific primers for reverse transcription quanti-
tative polymerase chain reaction (RTqPCR) experiments
in order to accurately quantify the levels of expression of
Figure 2 PharmGKB doxorubicin pharmacodynamic and pharmacokinetic pathways. Doxorubicin metabolic pathways were retrieved from
the PharmGKB website (http://www.pharmgkb.org/drug/PA449412#tabview=tab4&subtab=33), combined, and used for further analysis. All
diagrams are copyright PharmGKB. Used with permission from PharmGKB and Stanford University. (A) pharmacodynamics (B) Pharmacokinetics.
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the highly conserved AKR “1B” isoforms were observed by
microarray analysis with AKR1B probes that are not iso-
form-specific, we also designed isoform-specific RTqPCR
primers to accurately quantify transcript levels for the two
AKR 1B isoforms identified by microarray analysis. Finally,
since the carbonyl reductases (CBRs), like the AKRs, can
also play a role in the conversion of doxorubicin to doxor-
ubicinol [8,20], we designed isoform-specific primers to
quantify levels of transcripts for two CBR isoforms. The
data from these RTqPCR experiments (Figure 3A)
revealed that only the AKR1C2, AKR1C3 and AKR1B10
transcripts were significantly over-expressed in MCF-
7DOX2-12 cells compared to MCF-7CC12 cells (3.6-, 9.1-,
and 10.4-fold, respectively). CBR1 and CBR3 transcripts
were not differentially expressed in the doxorubicin-
resistant cells. As AKR1C3 exhibited one of the high-
est changes in expression, and since Akr1c3 has been
shown to efficiently convert doxorubicin to doxorubi-
cinol [21], we also assessed the expression of Akr1c3
protein in the cell lines. As shown in Figure 3B, im-
munoblotting experiments confirmed the considerably
higher expression of Akr1c3 in MCF-7DOX2-12 cells
relative to MCF-7CC12 cells.Doxorubicinol is 1 million-fold less cytotoxic than
doxorubicin in MCF-7 cells
Although it has been previously reported that doxorubi-
cinol is 20 to 27 times less cytotoxic than doxorubicin in
fibroblasts or pancreatic tumour cells [22,23], we also
wanted to assess in this study the relative sensitivity of
MCF-7DOX2-12 and MCF-7CC12 cells to doxorubicin and
doxorubicinol. As shown in Figure 4, the concentration
of doxorubicin required to reduce the number of col-
onies formed in a clonogenic assay by half (the IC50) was
7.8 ± 4.0 nM and 580 ± 91 nM for MCF-7CC12 and MCF-
7DOX2-12 cells, respectively, indicating a 74-fold resist-
ance to doxorobucin in MCF-7DOX2-12 cells. In contrast,
the IC50 of doxorubicinol for the MCF-7CC12 cell line
was 15 ± 1.6 mM, indicating a reduced cytotoxicity for
the metabolite of over 6 orders of magnitude! Interest-
ingly, the cytotoxicity of doxorubicinol was even less in
MCF-7DOX2-12 cells. In fact, we could not achieve suffi-
cient cytotoxcity to compute an IC50 value. Conse-
quently, in our study, doxorubicinol cytotoxicity in a
clonogenic assay was dramatically less than doxorubicin,
suggesting that the conversion of doxorubicin to doxor-
ubicinol by AKRs or CBRs would essentially eliminate
its cytotoxicity in breast tumour cells in culture.
Figure 3 Gene and protein expression levels of doxorubicin to doxorubicinol metabolizing enzymes. (A) Relative changes in expression
between MCF-7CC12 and MCF-7DOX2-12 cells were assessed by RTqPCR. Each sample was normalized first to RPS28 for loading and then to the
average expression of MCF-7CC12 cells to determine fold change. * p≤ 0.05, ** p≤ 0.01. (B) Western blot analysis of AKR1C3 expression in
MCF-7DOX2-12 and MCF-7CC12 whole cell lysates.
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to doxorubicin
As illustrated in Figure 4, treatment of MCF-7DOX2-12
cells with both doxorubicin and 5β-cholanic acid, a po-
tent inhibitor of AKR1B10 [24], AKR1C2, and AKR1C3
activity [25], almost fully restored doxorubicin sensitivity
to that of MCF-7CC12 cells (IC50 of 22.9 ± 9 nM). In con-
trast, treatment of MCF-7CC12 cells with 5β-cholanic
acid and doxorubicin had little effect on doxorubicin
sensitivity (IC50 of 14.1 ± 8.0 nM), suggesting insufficient
AKR activity in these cells to affect doxorubicin sensitiv-
ity. Addition of 5β-cholanic acid had no effect onFigure 4 Doxorubicin and doxorubicinol cytotoxicity in MCF-7CC12 an
acid. MCF-7CC12 and MCF-7DOX2-12 cells were assessed for their sensitivity t
AKR1B10, AKR1C2, and AKR1C3 inhibitor 5β-cholanic acid using a clonogensensitivity of MCF-7CC12 cells to doxorubicinol (IC50 of
7.5 ± 10.6 mM). However, addition of 5β-cholanic acid to
MCF-7DOX2-12 cells did appear to increase their sensitiv-
ity to doxorubicinol to a barely detectable range (IC50 of
3.2 ± 1.7 mM), suggesting a possible ability of the inhibi-
tor to affect further metabolism of doxorubicinol in
doxorubicin-resistant cells.
Restoration of doxorubicin sensitivity is accompanied by
restored nuclear localization in MCF-7DOX2-12 cells
Since doxorubicin is a fluorescent, DNA-binding topo-
isomerase II inhibitor [1,2], it localizes to the nucleus ind MCF-7DOX2-12 cells upon treatment with or without 5β-cholanic
o doxorubicin and doxorubicinol in the presence or absence of the
ic assay.
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tored by incubating cells with doxorubicin, and removing
extracellular drug by extensive washing of the cells, fol-
lowed by confocal laser scanning fluorescence micros-
copy [26]. We used this approach to visualize the
location of doxorubicin (red fluorescence) in MCF-7CC12
and MCF-7DOX2-12 cells in the presence of DRAQ5, a
highly cell-permeable DNA-binding dye that fluoresces
into the infra-red region of the electromagnetic spectrum
(shown as pseudo-blue fluorescence). As shown in
Figure 5A, we found that fluorescence of 0.5 μM doxo-
rubicin localized to nuclei in MCF-7CC12 cells, as
expected (Figure 5). There was strong co-localization of
doxorubicin and DRAQ5 fluorescence (bright purple
fluorescence). In MCF-7DOX2-12 cells, however, greatly
reduced doxorubicin fluorescence was observed, likely
due to the reduced uptake of doxorubicin into these cells,
as we previously reported [27]. In addition, the little
fluorescence that was visible was extra nuclear (as visua-
lized by a lack of co-localization with DRAQ5 staining),
and this fluorescence was clustered in the perinuclear re-
gion. These observations are consistent with those pre-
viously reported by Coley and colleagues for other
doxorubicin-resistant cell lines [26]. In previous experi-
ments, we observed that doxorubicin fluorescence in MCF-
7DOX2-12 cells co-localized with Lysotracker™ [17] but not
Mitotracker™ (Life Technologies, Burlington, VT) staining
(data not shown), suggesting that the drug was sequestered
in lysosomes and not bound to mitochondrial DNA. The
inability of doxorubicin to reach its target (nuclear DNA)
can clearly account for the reduced cytotoxicity of doxo-
rubicin observed in MCF-7DOX2-12 cells. However, it is un-
clear whether the perinculear fluorescence exhibited in
MCF-7DOX2-12 cells was from doxorubicin or perhaps aFigure 5 Intracellular localization of doxorubicin and doxorubicinol in
without 5β-cholanic acid. Cells were treated for 24 h with doxorubicin or
AKR1C3, and AKR1B10 inhibitor 5β-cholanic acid. After treatment for 24 h,
counterstain for 15 minutes, and then coverslips were mounted and imagemetabolite of doxorubicin that retains its fluroescence, such
as doxorubicinol. As shown in Figure 5A, when identical
experiments were performed with the equally fluorescent
doxorubicinol, intracellular fluorescence was even weaker
for MCF-7DOX2-12 cells. This may reflect a reduced and
greatly reduced ability of doxorubicinol to enter MCF-
7CC12 and MCF-7DOX2-12 cells, respectively. When micro-
scope settings were adjusted to improve detection of these
weak signals (Figure 5B), it was clear that doxorubicinol,
unlike doxorubicin, localized outside of the nucleus in both
cell lines, suggesting that the metabolite cannot reach or
bind its target. This raises the prospect that some of the
extra nuclear doxorubicin in MCF-7DOX2-12 cells may, in
fact, be doxorubicinol or another fluorescent doxorubicin
metabolite. However, the doxorubicin fluorescence in
MCF-7DOX2-12 cells is much more concentrated in the peri-
nuclear region and not as diffuse as doxorubicinol, suggest-
ing the drug and its metabolite occupy distinct locations
within cells.
We then assessed whether co-treatment of cells with
5β-cholanic acid altered doxorubicin or doxorubicinol
localization (Figure 5). Interestingly, 200 μM 5β-cholanic
acid was able to completely restore doxorubicin
localization to the nucleus of MCF-7DOX2-12 cells, sug-
gesting that the conversion of doxorubicin to doxorubi-
cinol does alter the drug’s ability to reach or bind its
target. The same concentration of 5β-cholanic acid,
however, had no effect on doxorubicinol localization in
MCF-7CC12 and MCF-7DOX2-12 cells.
Doxorubicinol fails to accumulate in MCF-7CC12 and
MCF-7DOX2-12 cells
After incubation with 0.5 μM doxorubicin, we used high
performance liquid chromatography to assess the levelMCF-7CC12 and MCF-7DOX2-12 cells upon treatment with or
doxorubicinol (red) in the presence or absence of the AKR1C2,
the nuclear dye DRAQ5 (blue) was added to the media as a
d by confocal fluorescence microscopy.
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MCF-7DOX2-12 cells and in the medium in which they
grew. As shown in Figure 6, there was no detectable
doxorubicinol in doxorubicin-treated MCF-7CC12 cells
or in their cell culture medium, suggesting minimal ex-
pression of AKRs or CBRs. However, we surprisingly did
not detect any doxorubicinol in MCF-7DOX2-12 cells or
their medium, despite their higher levels of expressionFigure 6 Intracellular levels of doxorubicin or doxorubicinol in
the presence or absence of 5β-cholanic acid or cyclosporine A,
measured by HPLC. MCF-7CC12 and MCF-7DOX2-12 cells were treated
for 24 h with 0.5uM doxorubicin or doxorubicinol, 200uM
5β-cholanic acid, and/or 5uM cyclosporine A. After treatment,
cellular and media extracts were prepared and assessed for
doxorubicin or doxorubicinol content by HPLC: (A) Treatment with
doxorubicinol and 5β-cholanic acid: 1 = no treatment; 2 = 0.5uM
doxorubicinol; 3 = 0.5uM doxorubicinol and 200uM 5β-cholanic acid,
(B) Treatment with doxorubicin, 5β-cholanic acid, and/or
cyclosporine A: 1 = no treatment; 2 = 0.5uM doxorubicin; 3 = 0.5uM
doxorubicin + 200uM 5β-cholanic acid; 4 = 0.5uM doxorubicin + 5uM
cyclosporine A; 5 = 0.5uM doxorubicin + 200uM 5β-cholanic
acid + 5uM cyclosporine A. The symbol # represents differences
between MCF-7CC12 and MCF-7DOX2-12 cells (treatment 2) with a
p value≤ 0.01. The symbols * and ** represent significant differences
between treatments at p values of≤ 0.05 and≤ 0.01, respectively.of AKR isoforms in the cells. Added doxorubicinol to
cells could be extracted and quantified in the medium
and in cells (Figure 6A), suggesting that the negative re-
sult was not due to an inability of the method to detect
doxorubicinol. Treatment of either cell line with 5β-
cholanic acid did not affect the intracellular level of dox-
orubicinol or the levels of doxorubicinol in the media.Intracellular levels of doxorubicin are significantly altered
upon treatment of MCF-7DOX2-12 cells with 5β-cholanic
acid and/or cyclosporine A
Treatment of MCF-7CC12 cells with 5β-cholanic acid
and the pan ABC transporter inhibitor cyclosporine A
increased cellular doxorubicin content by 51% and 80%,
respectively (Figure 6B). Addition of both agents increased
doxorubicin content to almost twice that of untreated
cells, but none of the above differences in doxorubicin
content were considered statistically significant. In con-
trast, 5β-cholanic acid or cyclosporine A significantly
increased doxorubicin content in MCF-7DOX2-12 cells by
2.8-fold (Figure 6B). Treatment of MCF-7DOX2-12 cells
with both 5β-cholanic acid and cyclosporine A increased
cellular doxorubicin content to levels 4.4-fold higher
than untreated cells (Figure 6B). These differences rela-
tive to untreated cells were found to be highly significant,
and are likely due to the increased expression of AKRs
[17] and ABC drug transporters known to be over-
expressed in MCF-7DOX2-12 cells, including Abcc1 [27].Doxorubicinol binds to DNA with lower affinity than
doxorubicin
We theorized that doxorubicinol does not localize to
the nuclei of MCF-7CC12 and MCF-7DOX2-12 cells be-
cause the hydroxylation of doxorubicin reduces its af-
finity for DNA. To test this hypothesis, we compared
the DNA binding parameters of doxorubicin and dox-
orubicinol using a binding displacement assay described
in Methods. As shown in Figure 7 and Additional file
3: Table S3, both Bmax and Kapp were substantially dif-
ferent between doxorubicinol (0.667 ± 0.013 and 0.679 ±
0.034 μM, respectively) and doxorubicin (0.903 ± 0.012
and 0.412 ± 0.017 μM, respectively), suggesting that, on a
molar basis, doxorubicinol binds to DNA with a much
lower affinity and capacity than doxorubicin.Discussion
Use of the binomial statistic to interpret the significance
of pathways in gene expression data
DNA microarray, high throughput quantitative PCR,
and other gene profiling approaches have been highly
useful in identifying differences in gene expression be-
tween cells or tumours responding to chemotherapy
Figure 7 Relative DNA binding affinity of doxorubicin and
doxorubicinol measured by a FID assay. Relative DNA binding
affinity of doxorubicin and doxorubicinol was measured by adding
consecutive aliquots of either doxorubicin or doxorubicinol to
ethidium bromide-saturated salmon sperm DNA. Addition of the
doxorubicin or doxorubicinol displaced the ethidium bromide and
resulted in a progressive net decrease in fluorescence at excitation
545 nm and emission 595 nm.
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discovery rate for such approaches is quite high, largely
due to the identification of a large number of “passenger
genes” unrelated to drug response. A wide variety of
pathway analysis tools exist today, some manually
curated, and some created primarily through machine
learning. PharmGKB [28], Ariadne Pathway Studio [29],
Reactome [30], Ingenuity Pathway Analysis (http://www.
ingenuity.com/), GenMAPP [31], and DAVID [32], are
examples of available tools which can be used to map
changes in gene expression to alterations in biochemical
pathways. The difficulty with this approach is the sheer
size of the data sets, the large number of documented
pathways, and the complex statistics required to deter-
mine the significance of findings. In this study we
elected to use a simple model to examine the biology of
doxorubicin resistance, namely looking for “over-
representation” of doxorubicin pharmacokinetic and
pharmacodynamic genes in datasets of genes having
altered expression in doxorubicin resistance.
In order to assess the feasibility of this approach and
to survey the broadest number of genes, we used Agilent
full genome microarrays containing 27,958 Entrez gene
probes, unlike our previous study of only 1720 gene
probes [17]. This approach helped to uncover a number
of AKRs induced during selection for doxorubicin resist-
ance, including AKR1C1, AKR1B1, AKR1B10, and
AKR1C3. Their expression was elevated between 4.5-
and 13.4-fold (Additional file 1: Table S1). Given that the
probes for these AKRs on the Agilent microarrays werenot isoform-specific, we used RTqPCR with isoform-
specific primers (Table 4) to determine that, upon selec-
tion for doxorubicin resistance, transcripts for AKR1C2,
AKR1C3, and AKR1B10 were overexpressed 3.6-, 9.1-,
and 10.4-fold, respectively (Figure 3). In addition to the
AKRs, other over-represented genes (Figure 2) provide
further insight into other proteins that likely contribute
to doxorubicin resistance. For example, NQO1 codes for
NAD(P)H dehydrogenase quinone 1, which plays a role
in converting doxorubicin to doxorubicin deoxyaglycone
or to doxorubicin semiquinone (Figure 2). Its 3-fold in-
crease in expression might therefore increase the con-
version of doxorubicin to these metabolites as well.
Transcripts for the drug efflux pump Abcc1 were also
upregulated 8.3-fold, as well as transcripts for other
ATP-binding cassette (ABC) transporters such as Abcd3,
Abcg2, and Abca1. In addition, a gene (SLC22A15) hom-
ologous to the solute carrier protein Slc22a16 (which
promotes doxorubicin uptake into cells [33]) was found
to be down regulated by 2.8-fold. The combined changes
in the expression of ABC transporters and solute carrier
proteins would be expected to reduce doxorubicin accu-
mulation into cells. The gene for catalase (CAT) was
found to be upregulated 3.6-fold in MCF-7DOX2-12 cells.
Since its gene product helps protect cells from oxidative
damage by reactive oxygen species [34], its elevated ex-
pression would protect cells from reactive oxygen spe-
cies known to be generated by doxorubicin. Genes
associated with the cardiotoxicity of doxorubicin
(through negative effects on mitochondrial function
when converted to doxorubicinol) also have altered ex-
pression in breast tumour cells upon selection for doxo-
rubicin resistance, including ACO1, ATPS, CYCS, and
ATP2B4 (Figure 2 and Additional file 1: Table S1).
Of the above-described changes in gene expression,
the greatest were for the AKRs. Evidence provided in
this study supports their substantial role in doxorubicin
resistance in tumour cells in vitro, and possibly in the
tumours of cancer patients. While many of the changes
in gene expression identified in our microarray study
likely play a bona fide role in doxorubicin resistance
(given their roles in cells), some of the identified genes
may not be the “drivers” of drug resistance, but change
expression through the altered expression of the driver
genes.
Role of the AKRs in resistance to doxorubicin
A role for AKRs in xenobiotic and anthracycline metab-
olism has already been well established in the literature
[21,35-37]. We also published previously that aldo-keto
reductases (AKRs) are overexpressed upon acquisition of
anthracycline resistance, that doxorubicin localization to
the nucleus is altered in doxorubicin-resistant cells, and
that inhibition of AKRs restores doxorubicin sensitivity
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study significantly extends these observations in many
respects. For example, it reveals that the expression of
other members of the AKR family is elevated as breast
tumour cells acquire resistance to doxorubicin. This
would further increase the production of doxorubicinol
and its possible conversion to other downstream meta-
bolites. Moreover, our study provides a detailed com-
parison between doxorubicin and doxorubicinol in
terms of their cytotoxicity, subcellular localization, and
DNA binding activity.
Interestingly, despite having identical fluorescence
capacities, cellular levels of doxorubicinol in both MCF-
7CC12 and MCF-7DOX2-12 cells was considerably lower
than that of doxorubicin (as measured by cellular fluor-
escence intensity after drug administration and washing
away free drug not taken up by cells). This decreased
doxorubicinol uptake may be because hydroxylated
doxorubicin is more polar and less able to traverse the
hydrophobic plasma membrane. Moreover, even if the
confocal microscope settings are modified to allow
greater sensitivity to detect cellular doxorubicinol, dox-
orubicinol was found not to be localized to the nucleus
in both MCF-7CC12 and MCF-7DOX2-12 cells. This indi-
cates that the differential localization of doxorubicin be-
tween MCF-7CC12 and MCF-7DOX2-12 cells may be due
to the strongly elevated conversion of doxorubicin to
doxorubicinol (or other fluorescent metabolites) in
MCF-7DOX2-12 cells. This may be why “doxorubicin” had
an altered location in anthracycline-resistant cells in our
previous study. The fluorescence observed in lysosomes
may be that of doxorubicin, but also of doxorubicinol
and other fluorescent doxorubicin metabolites. Consist-
ent with this view, and not reported in our previous study,
the administration of the AKR inhibitor 5β-cholanic acid
significantly restored “doxorubicin” localization to the
nucleus. More likely the inhibitor prevented doxorubicin
conversion to doxorubicinol, permitting more doxorubicin
to be retained within the nucleus.
What could account for the decreased localization of
doxorubicin to the nucleus? We report in the current
study that doxorubicinol has significantly lower ability to
bind to DNA than doxorubicin (altered Bmax and Kapp).
The conversion of doxorubicin to doxorubicinol by
AKRs would result in reduced binding to DNA and
hence less ability of the drug to remain associated with
the nucleus. In our previous study, we did not differenti-
ate between the cellular localization of doxorubicin and
doxorubicinol.
One surprising finding in our study was the lack of de-
tection of significant doxorubicinol in MCF-7DOX2-12
cells (Figure 6). This was despite the elevated expression
of a number of AKRs in the cell line (Figure 3),
which would be expected to covert doxorubicin todoxorubicinol. And yet, the addition of 5β-cholanic
acid with doxorubicin increased the cellular content of
doxorubicin (Figure 6), supporting the observation that
5β-cholanic acid is able to block the conversion of
doxorubicin to doxorubicinol. What may account for
the discrepancy in these points of view? One possibility
is that 5β-cholanic acid blocks the efflux of doxorubicin
by drug transporters (possibly Abcc1), thereby increasing
the retention of doxorubicin in cells. One argument
against this hypothesis is that both 5β-cholanic acid and
cyclosporine A increased cellular doxorubicin content
(Figure 6), the latter being a known inhibitor of Abcc1
function [38]. The combination of both agents increased
cellular doxorubicin content further, suggesting that they
were acting by distinct mechanisms. Moreover, unlike
5β-cholanic acid (Figure 4), addition of cyclosporine
A had no effect on the cytotoxicity of doxorubicin in
MCF-7DOX2-12 cells, as measured in a clonogenic assay
[27]. Finally, another inhibitor of AKR catalytic activity
with a structure very distinct from cyclosporine A (flu-
fenamic acid) also restored doxorubicin cytotoxicity and
nuclear localization in MCF-7DOX2-12 cells (data not
shown). This suggests that it is the ability of these agents
to inhibit AKR activity that is responsible for the restor-
ation of drug cytotoxicity. An alternative argument is
that the doxorubicinol, once formed, is further metabo-
lized, such that the metabolite is not retained in the
method used to extract cellular doxorubicin and doxoru-
bicinol for HPLC-based measurements. Thus, doxorubi-
cinol would not be seen to accumulate in MCF-7DOX2-12
cells.
Despite the ability of both cyclosporin A and 5β-
cholanic acid to increase cellular doxorubicin content in
MCF-7DOX2-12 cells, why was only the latter agent able
to appreciably restore doxorubicin cytotoxicity? Increasing
the cellular content of doxorubicin by the cyclosporine-
mediated reduction of drug efflux may not sufficiently in-
crease its cytotoxicity if the additional cellular doxorubicin
is rapidly converted to doxorubicinol by the elevated ex-
pression of AKRs and/or if the additional doxorubicin is
sequestered into lysosomes. In contrast, AKR inhibition
may block all conversion of doxorubicin to doxorubicinol,
such that any drug entering the cell remains as doxorubi-
cin and is able to rapidly reach the nucleus, before being
sequestered.
Conclusions
Using a full genome approach, this study provides im-
portant new insight into pharmacokinetic and pharma-
codynamic pathways that are altered upon selection of
cells for resistance to doxorubicin. In addition to our
previously reported finding of increased expression of
the AKR 1C isoforms [17], the current study reveals
other changes in gene expression that would be expected
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genes that may: decrease uptake of doxorubicin
(SLC22A15), enhance efflux of doxorubicin (ABCC1,
ABCG2, ABCD3, ABCA1), enhance conversion of doxo-
rubicin to doxorubicinol (AKR1B10, AKR1B1), doxo-
rubicin deoxyaglycone or doxorubicin semiquinone
(NQO1), and inhibit the ability of doxorubicin to dam-
age tumour cells through the generation of reactive
oxygen species (CAT). Moreover, this study provides
an in-depth comparison of the biochemical properties
of doxorubicin versus doxorubicinol. While the former
is highly cytotoxic, has high DNA binding affinity, and
localizes to the nucleus in wildtype breast tumour cells,
doxorubicinol is over a million times less cytotoxoic,
has significantly reduced DNA binding activity, and is
retained in the cytoplasm or lysosomes of cells. We also
show that the administration of AKR inhibitors with
doxorubicin in MCF-7DOX2 cells substantially restores
both drug localization to the nucleus and drug cytotox-
icity. Interestingly, doxorubicinol is highly cardiotoxic,
and it is believed that doxorubicinol is responsible for
the cardiotoxicity associated with doxorubicin chemo-
therapy [39,40]. Since the AKR inhibitor 5β-cholanic
acid is a well-tolerated naturally occurring bile acid in
humans, and since flufenamic acid has been used in
clinical trials with manageable toxicities [41], there may
be significant value in conducting clinical trials in which
either 5β-cholanic acid or flufenamic acid are co-
administered with doxorubicin during chemotherapy.
Results in this study would suggest that these AKR inhi-
bitors may increase tumour levels of doxorubicin and
block cardiotoxicity induced by doxorubicin conversion
to doxorubicinol. This may dramatically improve the
therapeutic index of doxorubicin when administered to
cancer patients and improve the duration of clinical re-




Supplies and reagents used in this study came from a
variety of sources. Unless otherwise noted, Sigma (St.
Louis, MO) was the supplier.
Cell culture
MCF-7 breast adenocarcinoma cells were obtained from
the American Tissue Culture Collection (ATCC) (lot
HTB-22) and selected for resistance to doxorubicin (Pfi-
zer Pharmaceuticals, St. Laurent, QC) as previously
described [27]. Briefly, doxorubicin-sensitive, wildtype
MCF-7 cells were grown in progressively increasing con-
centrations of doxorubicin from 1000x below the IC50
for the drug in parental MCF-7 cells (dose 1) to its
maximally tolerated dose (dose 12) in 1.5- or 3-foldincrements, with retention of cells surviving the greater
of the two doses. Cells selected for survival in the vary-
ing doses of doxorubicin were termed MCF-7DOX2 cells.
A “co-cultured control” cell line was selected under
identical conditions in the absence of drug (MCF-7CC
cells). These cells served as a control to help identify
changes in gene expression due to long-term cell cul-
ture. The highest dose level to which cells were selected
are indicated in the subscript of the cell line name. For
example, MCF-7DOX2-12 cells refers to cells selected to
the 12th dose level of doxorubicin. The 2 in the subscript
is to prevent confusion with a previously isolated
doxorubicin-resistant cell line in our laboratory (MCF-
7DOX). All cells used in this study were selected to dose
level 12 (0.1 μM doxorubicin). Cells were grown in high-
glucose DMEM medium (Fisher Scientific, Nepean, ON)
supplemented with penicillin-streptomycin (Fisher) and
10% fetal bovine serum (Fisher) in 75 cm2 tissue culture
flasks (Sarstedt Canada, Montreal, QC), unless otherwise
noted. Cells were maintained at 37°C in air supplemen-
ted with 5% CO2 in a humidified environment. Cells
were passaged weekly, with a medium change once be-
tween passages. Drug-resistant cells were maintained in
medium containing doxorubicin at their selection dose.
Microarray analysis
Changes in gene expression between MCF-7CC12 and
MCF-7DOX2-12 cells were identified by microarray ana-
lysis using Agilent 4x44k whole human genome arrays
(product number G4112F; Agilent Technologies, Missis-
sauga, ON). These arrays enabled us to determine the
level of expression of 27,958 human Entrez genes (close
to the entire genome). Five hundred ng of total RNA,
isolated with a Qiagen RNeasy kit (Mississauga, ON),
was used for each sample. The RNA was then labeled
with Cy3 or Cy5 using an Agilent Quick Amp labeling
kit (Product #5190-0444). Hybridization was performed
as per the manufacturer’s protocol. Experiments were
repeated using multiple batches of labeled RNA, with
both forward and reverse-labeling to account for dye
bias, for a total of 16 two-colour arrays. The microarrays
were scanned, and feature extraction and background in-
tensity corrections were performed with Agilent software
(v.10.7.3.1). Using Partek Genomics suite (St. Louis,
MO) to perform a 4 way ANOVA using the Method of
Moments [42], a list of genes significantly over- or under-
expressed in MCF-7DOX2-12 cells relative to MCF-7CC12
cells. The false discovery rate was set at 0.01, with only
genes changing expression by ≥ 2-fold being noted. The
four variables assessed in the 4 way ANOVA were the
cell line (MCF-7CC12 cells versus MCF-7DOX2-12 cells),
the dye used (Cy3 versus Cy5), the experimental batch of
arrays (to address batch effects) and the arrays them-
selves to address random effects. The input file was the
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pression between MCF-7DOX2-12 and MCF-7CC12 cells.
The model used was: Yijklm= μ+Cell line (i) +Dye (j) +
Exp batch (k) + arrays (random effect) (kl) + εijklm, where
Yijklm represents the mth observation on the ith Cell
line jth Dye kth Exp batch lth arrays, μ is the common ef-
fect for the whole experiment, εijklm represents the ran-
dom error present in the mth observation, on the ith Cell
line, jth Dye, kth Exp batch, lth arrays. The errors εijklm
were assumed to be normally and independently distribu-
ted , with mean 0 and standard deviation δ for all mea-
surements. Arrays and Exp batch were considered
random effects. Normalized expression was transformed
to the base 2.0, with p values reported for significance of
differences in the expression of each gene. The output of
the analysis was a p value for the significance of the
observed fold change in expression of a particular gene
and for the mean ratio of expression of a particular gene
between the two cell lines. The microarray data was
deposited in the NCBI Gene Expression Omnibus (GEO)
database, accession number GSE27254) in accordance
with MIAME standards [15]. The url to access this data
is: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
dbezngycywquuhm&acc=GSE27254.
To confirm the isogenic nature of the two cell lines, a
Significance Analysis of Microarrays (SAM) plot was
created using the freely-available microarray software
TM4 suite [43], with the following workflow:
(1) Agilent raw data was converted to .MEV format
using TIGR Express Converter v2.1.
(2) The MEV files were then normalized using TIGR
MIDAS v2.22 and a LOWESS normalization filter
with flip-dye consistency checking where
appropriate.
(3) A one-class Significance Analysis of Microarrays
(SAM) analysis was performed using TIGR MEV
v4.6.1.
For pathway analysis, the list of significant differentially-
expressed genes generated by Partek Genomics Suite was
compared to a curated list of genes, transcripts or proteins
shown to be involved in doxorubicin pharmacokinetics and
pharmacodynamics in tumour cells or cardiomyocytes,
available from the Pharmacogenomics Knowledge Base
(PharmGKB) [16,28]. These lists were then compared in
S-Plus (v8.0) using the binomial statistical test as previously
described [14].
RNA extraction, reverse transcription, and quantitative
polymerase chain reaction
Given that the 1C and 1B AKR isoforms are highly con-
served and that the probes for the 1C and 1B AKR tran-
scripts on the Agilent 4X44 microarrays were notisoform-specific, we designed isoform-specific 1C and
1B primers to accurately quantify the levels of expres-
sion of the various 1C and 1B transcripts. These primers
(Table 4) and isoform-specific primers for the carbonyl
reductases (which also convert doxorubicin to doxorubi-
cinol) were used in RTqPCR experiments. Total RNA
was extracted from the MCF-7CC12 and MCF-7DOX2-12
cell lines using a Qiagen RNeasy kit (Mississauga, ON),
reverse transcribed, and the cDNAs amplified using an
ABI 7900HT quantitative PCR machine and SYBR
Green 1 detection chemistry as described previously
[44]. After RNA extraction and before reverse transcrip-
tion, RNA was quantified and quality ensured using an
Agilent Bioanalyzer 2100 RNA nano kit. 2 μg of RNA
was then DNase I (Invitrogen) treated. For reverse tran-
scription, either MMLV reverse transcriptase (Invitro-
gen, Burlington, ON) and an oligo-dT20 primer, or
Superscript III reverse transcriptase (Invitrogen) and an
AKR1C-specific reverse transcription primer were used,
all according to the manufacturer’s protocol. The cDNA
was then stored at −20°C until analysis via the ΔCT
method. All experiments were performed according to
MIQE standards [45]. Primers used for reverse tran-
scription or to amplify specific cDNAs are described in
Additional file 4: Table S4.
Protein extraction and quantification
Ten cm plates of cells (cultured for 2 passages without
drug to 80% confluence) were rinsed twice in Dulbecco’s
PBS, removed of excess liquid using a pipette tip, and
placed on ice. Three hundred to 1000 μl of RIPA buffer
(10 mM Tris–HCl, 1% sodium deoxycholate, 0.1% SDS,
1% Triton X-100, 150 mM NaCl, pH 7.5) with added
Complete™ protease inhibitors (Roche Diagnostics, Laval,
QC) were added to each plate, and the plates scraped
with a cell scraper. The resulting crude lysate was passed
through a 21 gauge needle 5 times. The lysate was incu-
bated on ice for 30 minutes and then centrifuged for
20 minutes at 13.2 × 103 ×g at 4°C. The supernatant was
retained and stored at −80°C. Protein concentrations in
extracts were measured using a BCA protein quantifica-
tion kit (Pierce Bioscience) using standard solutions of
Bovine Serum Albumin (BSA).
Western blotting
Forty μg of protein were diluted in 6x Laemelli loading
buffer and loaded onto a 10% SDS-PAGE gel with a 4%
stacking gel. The gel was also loaded with 5μL of Bio-
Rad (Mississagua, ON) dual colour protein marker. The
gels were subjected to electrophoresis in a Bio-Rad mini
tetra system at 80 V for 30 minutes and then at 120 V
for an additional 1 h. The gels were removed and the gel
proteins transferred to nitrocellulose membranes (GE
Healthcare, Baie d’Urfe QC) using a Bio-Rad semi-dry
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were then stained with 0.5% Ponceau S in 1% acetic acid
to confirm transfer efficiency and even protein loading.
The membranes were blocked in 5% skim milk powder
(Carnation) in 0.1% TBST (20 mM Tris–HCl, 150 mM
NaCl, 0.05% Tween 20, pH 7.5) for 1 h at room
temperature, and then incubated overnight at 4°C with
an isoform specific mouse monoclonal anti-AKR1C3
antibody [46] (Sigma) at a 1:2,000 dilution in 5% skim
milk powder in TBST. The membranes were then
washed with TBST for 15 minutes, and incubated in
HRP-conjugated goat anti-mouse secondary antibody
(Santa Cruz Biotechnology Inc., Santa Cruz, CA) at a
1:10,000 dilution in 5% skim milk powder in TBST for
1 h at room temperature. Membranes were again
washed in TBST for 15 minutes and subjected to
3 × 5 minute final washes in TBS before being covered in
ECL solution (Santa Cruz Biotechnology Inc.) and
imaged using a gel documentation system (Alpha Inno-
tech) for 10 minutes. An identical procedure using a
mouse monoclonal anti-β-tubulin antibody (Santa Cruz
Biotechnology Inc.) at a 1:10,000 dilution was used to
monitor β-tubulin levels in the extracts as a loading
control.
Confocal microscopy
Cells were plated on #1 coverslips placed in 6-well plates
and allowed to adhere overnight before being treated.
Treatment consisted of addition of 0.5 μM doxorubicin
or doxorubicinol (Toronto Research Chemicals Inc.,
North York, ON), and either 200 μM 5β-cholanic acid
(Steraloids, Newport, RI) or DMSO as a vehicle control.
After the 24 h treatment, DRAQ5 (Biostatus, Leicester-
shire, UK) was added to the culture media for 15 minutes
as a nuclear counterstain. The coverslips were rinsed
gently in 3 sequential PBS washes and sealed onto stand-
ard microscope slides using clear nail polish. After the
nail polish dried, cells were observed using a Zeiss LSM
510 META confocal laser scanning microscope using an
argon-ion laser at a 488 nm wavelength band for excita-
tion of doxorubicin and doxorubicinol and using a
560 nm long-pass filter to detect intrinsic fluorescence
of doxorubicin and its metabolites. A 633 nm laser with
a 650 nm long-pass filter was used to detect DRAQ5
fluorescence.
High-performance liquid chromatography
Cells (8.0 × 106 cells per 10 cm plate) were allowed to
adhere overnight, after which they were treated with
0.5 μM doxorubicin or 0.5 μM doxorubicinol (with or
without 5 μM cyclosporine A and/or 200 μM 5β-
cholanic acid) for 24 h. After this time period, the media
was decanted (with 0.5 mL reserved for HPLC analysis),
and the plates were rinsed twice in PBS. One mL of a0.2 M Na2HPO4 solution, pH 8.5, was added to the
plates and the cells were scraped off of the plate. A
0.5 ml volume of the same solution was added to the
0.5 mL of reserved media. Each sample was then added
to 4 mL of a 9:1 v/v chloroform:n-heptanol mixture in a
polypropylene 15 mL centrifuge tube and shaken on a
mixer for 20 minutes, after which the samples were cen-
trifuged for 10 minutes at 2000× g at 20°C. The bottom
organic layer was then aspirated from the tube using a
glass 5 mL pipette and dispensed into a new 15 mL cen-
trifuge tube containing 250uL of 0.1 M ortho-
phosphoric acid. Each tube was then mixed on a vortex
mixer for 30 seconds before being centrifuged for 2 min-
utes at 2000× g. The top 200μL of the upper aqueous
layer was then removed and stored at −80 degrees
Celsius for later analysis.
Separations were performed using a revised gradient
elution based on a previously described isocratic method
[17] on a Waters Alliance e2695 system with a Waters
2475 fluorescence detector set at 480 nm excitation and
560 nm emission. Chromatographic conditions were the
following: column: YMC CN 25× 5 mm column; Eluent
A: 10 mM NaH2PO4 pH 4.0, Eluent B: HPLC grade
CH3CN; flow rate: 1.0 mL/min. The gradient program
was as follows: 0 min = 20% B 80% A, 10 min = 50% B
50% A, 11 to 24 min = 20% B 80% A. The slope for each
gradient change was linear.
DNA binding affinity assay
The relative DNA binding affinity of doxorubicin and
doxorubicinol was determined by using a fluorescent
intercalator displacement assay [47]. Briefly, a quartz cu-
vette was filled with 3 mL of Tris buffer (0.1 M Tris,
0.1 M NaCl, pH 8.0; approximating conditions inside the
nucleus) to which 4.4 μM ethidium bromide was added.
A fluorescence reading (excitation: 545 nm, emission:
590 nm) was taken using a Perkin Elmer LS-50 fluorim-
eter; this constituted the baseline reading. Pre-sheared
salmon sperm DNA (8.8 μM in base pairs) was then
added to the cuvette, incubated for 5 minutes, and again
the fluorescence was determined; this constituted the
maximal or 100% reading. Aliquots of doxorubicin or
doxorubicinol (0.067 μM) were added to the cuvette,
incubated for 5 minutes, and the corresponding reading
recorded. The background reading was subtracted for
each reading and then divided by the maximal reading
to determine per cent of maximal binding. These data
were fit to curves to determine Kapp and Bmax values.
Measurement of drug sensitivity
Drug sensitivity was assessed using a variation [48] of
the standard clonogenic assay [49]. Briefly, for each con-
dition, 12 × 25 cm2 flasks were plated with 2.5 × 105 cells
and left to adhere overnight. The next day, each flask
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cin, decreasing in 3-fold increments, from 3.0 × 10-6 M
to 5.13 × 10-11 M, with a final flask receiving no doxo-
rubicin. After 24 h, cells were trypsinized, pelleted, and
resuspended in 300uL of medium which was then com-
bined with 2.7 mL of methyl cellulose growth medium
[2.6% methyl cellulose, (Shin-Etsu) and 30% FBS in
IMDM (Princess Margaret Hospital)]. After being mixed
thoroughly, the suspension was allowed to settle for
30 minutes before 1.2 ml of cells were introduced into
6-well tissue culture plates. Plates were incubated for
2 weeks and then 10 randomly selected fields in each
well were counted at 40x magnification.Statistical analyses
Graphpad Prism (v5.0) was used for all statistical tests
unless otherwise noted. Differences between treatment
means were assessed using either a Student’s unpaired
t-test or an unpaired 1-way Analysis of Variance (ANOVA)
with Tukey’s Honestly Significant Difference (HSD) post-
hoc test where appropriate. A p value ≤ 0.05 was consid-
ered significant.Additional files
Additional file 1: Table S1. Genes associated with doxorubicin
pharmacokinetics or pharmacodynamics in cancer cells or
cardiomyocytes as identified in the PharmGKB knowledgebase. Those
genes identical to and related to genes significantly changing expression
upon acquisition of doxorubicin resistance in MCF-7 breast tumour cells
by microarray analysis (false discovery rate of 0.01) are listed in bold
regular font and bold italics font, respectively. The fold change in gene
expression is also listed for upregulated (+) or down regulated (−) genes.
Additional file 2: Table S2. Over-representation of doxorubicin
pharmacokinetic or pharmacodynamic genes in the dataset of genes
associated with the acquisition of doxorubicin resistance in MCF-7 breast
tumour cells. The p values assessing the significance of this over-
representation are depicted in parentheses, with statistically significant p
values listed in bold font.
Additional file 3: Table S3. Differences in doxorubicin and
doxorubicinol DNA binding parameters. DNA binding by doxorubicin or
doxorubicinol was compared in an ethidium bromide displacement assay
as described in Materials and Methods. The Bmax and Kapp values for
doxorubicin and doxorubicinol are listed, along with the p values for
significant differences in their binding parameters (p < 0.05).
Additional file 4: Table S4. Primers used for measurement of
expression of candidate genes involved in doxorubicin hydroxylation by
quantitative PCR. Forward and reverse primers recognizing aldo keto-
reductases (AKRs) or carbonyl reductases (CRs) are listed, along with the
primers for the reference gene RPS28.Abbreviations
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